Search

Your search keyword '"Isnardi, C."' showing total 43 results
Start Over Author "Isnardi, C."
43 results on '"Isnardi, C."'

1. AB0068 LONG-TERM FOLLOW-UP OF PATIENTS WITH RHEUMATIC DISEASES AND SARS-CoV-2 INFECTION: DATA FROM THE SAR-COVID REGISTRY

Author

Isnardi, C. A., primary, Alfaro, M. A., additional, Virasoro, B. M., additional, Gómez, G., additional, D´angelo, M. E., additional, Saurit, V., additional, Petkovic, I. E., additional, Quintana, R., additional, Tissera, Y., additional, Pisoni, C., additional, Berbotto, G., additional, Haye Salinas, M., additional, Ornella, S., additional, Pera, M., additional, Reyes, A. A., additional, Baez, R., additional, Pereira, D. A., additional, Alle, G., additional, Castro Coello, V. V., additional, Alba, P., additional, Cogo, A. K., additional, Alonso, C. G., additional, Gobbi, C., additional, Gallino Yanzi, J., additional, and Pons-Estel, G., additional

Published
2024
Full Text
View/download PDF

2. Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID-19 Global Rheumatology Alliance Registry

Author

Yazdany, J, Ware, A, Wallace, Z, Bhana, S, Grainger, R, Hachulla, E, Richez, C, Cacoub, P, Hausmann, J, Liew, J, Sirotich, E, Jacobsohn, L, Strangfeld, A, Mateus, E, Hyrich, K, Gossec, L, Carmona, L, Lawson-Tovey, S, Kearsley-Fleet, L, Schaefer, M, Ribeiro, S, Al-Emadi, S, Hasseli, R, Müller-Ladner, U, Specker, C, Schulze-Koops, H, Bernardes, M, Fraga, V, Rodrigues, A, Sparks, J, Ljung, L, Di Giuseppe, D, Tidblad, L, Wise, L, Duarte-García, A, Ugarte-Gil, M, Colunga-Pedraza, I, Martínez-Martínez, M, Alpizar-Rodriguez, D, Xavier, R, Isnardi, C, Pera, M, Pons-Estel, G, Izadi, Z, Gianfrancesco, M, Carrara, G, Scirè, C, Zanetti, A, Machado, P, Wallace, ZS, Hausmann, JS, Liew, JW, Mateus, EF, Hyrich, KL, Ribeiro, SLE, Fraga, VM, Rodrigues, AM, Sparks, JA, Ugarte-Gil, MF, Colunga-Pedraza, IJ, Martínez-Martínez, MU, Xavier, RM, Isnardi, CA, Gianfrancesco, MA, Scirè, CA, Machado, PM, Yazdany, J, Ware, A, Wallace, Z, Bhana, S, Grainger, R, Hachulla, E, Richez, C, Cacoub, P, Hausmann, J, Liew, J, Sirotich, E, Jacobsohn, L, Strangfeld, A, Mateus, E, Hyrich, K, Gossec, L, Carmona, L, Lawson-Tovey, S, Kearsley-Fleet, L, Schaefer, M, Ribeiro, S, Al-Emadi, S, Hasseli, R, Müller-Ladner, U, Specker, C, Schulze-Koops, H, Bernardes, M, Fraga, V, Rodrigues, A, Sparks, J, Ljung, L, Di Giuseppe, D, Tidblad, L, Wise, L, Duarte-García, A, Ugarte-Gil, M, Colunga-Pedraza, I, Martínez-Martínez, M, Alpizar-Rodriguez, D, Xavier, R, Isnardi, C, Pera, M, Pons-Estel, G, Izadi, Z, Gianfrancesco, M, Carrara, G, Scirè, C, Zanetti, A, Machado, P, Wallace, ZS, Hausmann, JS, Liew, JW, Mateus, EF, Hyrich, KL, Ribeiro, SLE, Fraga, VM, Rodrigues, AM, Sparks, JA, Ugarte-Gil, MF, Colunga-Pedraza, IJ, Martínez-Martínez, MU, Xavier, RM, Isnardi, CA, Gianfrancesco, MA, Scirè, CA, and Machado, PM

Abstract

Objective: Approximately one third of individuals worldwide have not received a COVID-19 vaccine. Although studies have investigated risk factors linked to severe COVID-19 among unvaccinated people with rheumatic diseases (RDs), we know less about whether these factors changed as the pandemic progressed. We aimed to identify risk factors associated with severe COVID-19 in unvaccinated individuals in different pandemic epochs corresponding to major variants of concern. Methods: Patients with RDs and COVID-19 were entered into the COVID-19 Global Rheumatology Alliance Registry between March 2020 and June 2022. An ordinal logistic regression model (not hospitalized, hospitalized, and death) was used with date of COVID-19 diagnosis, age, sex, race and/or ethnicity, comorbidities, RD activity, medications, and the human development index (HDI) as covariates. The main analysis included all unvaccinated patients across COVID-19 pandemic epochs; subanalyses stratified patients according to RD types. Results: Among 19,256 unvaccinated people with RDs and COVID-19, those who were older, male, had more comorbidities, used glucocorticoids, had higher disease activity, or lived in lower HDI regions had worse outcomes across epochs. For those with rheumatoid arthritis, sulfasalazine and B-cell–depleting therapy were associated with worse outcomes, and tumor necrosis factor inhibitors were associated with improved outcomes. In those with connective tissue disease or vasculitis, B-cell–depleting therapy was associated with worse outcomes. Conclusion: Risk factors for severe COVID-19 outcomes were similar throughout pandemic epochs in unvaccinated people with RDs. Ongoing efforts, including vaccination, are needed to reduce COVID-19 severity in this population, particularly in those with medical and social vulnerabilities identified in this study.

Published
2024

3. POS0974 CARDIOVASCULAR OUTCOMES OF ANTI-TNF ALFA AND JAK INHIBITORS IN PATIENTS WITH RHEUMATOID AND PSORIATIC ARTHRITIS. REAL WORLD EVIDENCE AND INSIGHTS OF BIOBADASAR 3.0 REGISTRY

Author

Brigante, J. A., primary, Roberts, K., additional, Isnardi, C. A., additional, Gómez, G., additional, Holguín Arias, L. L., additional, Pons-Estel, B., additional, Gamba, J., additional, Haye, M., additional, Dapeña, J. M., additional, Secco, A., additional, Savio, V., additional, Soliz Cordero, C., additional, Gobbi, C., additional, Velozo, E., additional, Catay, E., additional, Aste, N., additional, Medina, G., additional, Exeni, I. E., additional, Gomez, G., additional, Pereira, D. A., additional, Granel, A. B., additional, Petkovic, I., additional, Pisoni, C., additional, Smichowski, A. M., additional, Sacnun, M., additional, Berbotto, G., additional, García, M., additional, Viola, M., additional, Bovea Castelblanco, G., additional, Saurit, V., additional, Kerzberg, E., additional, Larroude, M. S., additional, De La Sota, M. E., additional, Bertoli, A., additional, Diaz, M. P., additional, Castro, C., additional, Citera, G., additional, Casado, G., additional, Quintana, R., additional, Soriano, E., additional, Graf, C., additional, Pons-Estel, G., additional, and De la Vega, M., additional

Published
2023
Full Text
View/download PDF

4. AB1297 EFFECT OF ABO AND RH BLOOD TYPE ON SARS-CoV-2 INFECTION SEVERITY IN PATIENTS WITH RHEUMATIC DISEASES: DATA FROM THE NATIONAL SAR-COVID REGISTRY

Author

Valdez Donelli, F., primary, Carrizo Abarza, V., additional, Isnardi, C. A., additional, Schneeberger, E. E., additional, Citera, G., additional, D’Angelo, M. E., additional, Ornella, S., additional, Haye, M., additional, Alonso, C. G., additional, Severina, M., additional, Alle, G., additional, Cosatti, M., additional, Gallino Yanzi, J., additional, Medina, M. A., additional, Perez Alamino, R., additional, Lloves Schenone, N., additional, Correa, M. D. L. A., additional, De la Vega, M., additional, Carlevaris, L., additional, Cucchiaro, N., additional, Bertoli, A., additional, Calvo, M. E., additional, Córdoba, M. C., additional, Martire, V., additional, Petruzzelli, S., additional, Kisluk, B., additional, Muñoz, L., additional, Gomez, G., additional, Diaz, M. P., additional, Gómez Vara, A. B., additional, Soares de Souza, S., additional, Velasco Zamora, J. L., additional, Castaño, M. S., additional, Morales, N. S., additional, Mamani Ortega, M. L., additional, Gómez, G., additional, Roberts, K., additional, Quintana, R., additional, and Pons-Estel, G., additional

Published
2023
Full Text
View/download PDF

5. POS0156 BONE DENSITY, MICROSTRUCTURE AND BIOMECHANICS OVER A 7-YEAR OBSERVATION PERIOD IN RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS - INFLUENCE OF AUTOIMMUNITY, DISEASE ACTIVITY AND BIOLOGICAL DMARD TREATMENT

Author

Kemenes, S., primary, Tascilar, K., additional, Kleyer, A., additional, Minopoulou, I., additional, Fagni, F., additional, Zekovic, A., additional, Isnardi, C. A., additional, Liphardt, A. M., additional, Bayat, S., additional, Schuster, L., additional, Schett, G., additional, and Simon, D., additional

Published
2023
Full Text
View/download PDF

6. AB1666 CLUSTER ANALYSIS TO IDENTIFY PATIENT GROUPS AND ASSESS THE PRESENCE OF ADVERSE EVENTS. REAL WORLD EVIDENCE FROM THE BIOBADASAR 3.0 REGISTRY

Author

Brigante, J. A., primary, Roberts, K., additional, Isnardi, C., additional, Gómez, G., additional, Haye, M., additional, García, M., additional, Gobbi, C., additional, Casado, G., additional, Holguín Arias, L. L., additional, Dapeña, J. M., additional, Papasidero, S., additional, Berbotto, G., additional, Viola, M., additional, Saurit, V., additional, Petkovic, I., additional, Bertoli, A., additional, Diaz, M. P., additional, Catay, E., additional, Exeni, I. E., additional, Pons-Estel, B., additional, Bovea Castelblanco, G., additional, De La Sota, M. E., additional, Larroude, M. S., additional, Pereira, D. A., additional, Granel, A. B., additional, Medina, G., additional, Pisoni, C., additional, Sacnun, M., additional, Velozo, E., additional, Aste, N., additional, Castro, C., additional, Kerzberg, E., additional, Savio, V., additional, Gamba, J., additional, Secco, A., additional, Citera, G., additional, Soriano, E., additional, Graf, C., additional, Pons-Estel, G., additional, and De la Vega, M., additional

Published
2023
Full Text
View/download PDF

7. AB1341 COVID-19 IN PATIENTS WITH RHEUMATIC IMMUNE-MEDIATED INFLAMMATORY DISEASES IN AMERICA: DIFFERENCES AND SIMILARITIES BETWEEN MEXICO AND ARGENTINA

Author

Isnardi, C. A., primary, Alpizar-Rodriguez, D., additional, Martínez-Martínez, M. U., additional, Quintana, R., additional, Petkovic, I. E., additional, Ornella, S., additional, Castro Coello, V. V., additional, Velozo, E., additional, Zelaya, D., additional, Severina, M., additional, Cogo, A. K., additional, Nieto, R., additional, Pereira, D. A., additional, Colunga-Pedraza, I. J., additional, Irazoque-Palazuelos, F., additional, Reyes Cordero, G. C., additional, Rodriguez-Reyne, T. S., additional, Veloz Aranda, J. A., additional, Skinner Taylor, C. M., additional, Juarez Mora, I. M., additional, Zazueta Montiel, B. E., additional, Martínez, A., additional, Pacheco Tena, C. F., additional, and Pons-Estel, G., additional

Published
2023
Full Text
View/download PDF

8. AB1329 CLINICAL CHARACTERISTICS OF SARS-CoV-2 INFECTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN ARGENTINA: DATA FROM THE SAR-COVID NATIONAL REGISTRY

Author

Isnardi, C. A., primary, Roberts, K., additional, Tissera, Y., additional, Petkovic, I., additional, Berbotto, G., additional, Gobbi, C., additional, Tanten, R., additional, Cogo, A. K., additional, Asnal, C., additional, Baños, A. R., additional, Vivero, F., additional, Schmid, M., additional, Lazaro, M. A., additional, German, N., additional, Takashima, L., additional, Scafati, J., additional, Werner, M. L., additional, Casalla, L., additional, De la Vega Fernandez, S. S., additional, Castrillon Bustamante, D., additional, Rodriguez, F., additional, Moyano, S., additional, Martin, M. L., additional, Cosentino, V., additional, Herscovich, N., additional, Tralice, E. R., additional, Barbich, T., additional, Vasquez, D. L., additional, Buschiazzo, E., additional, Maid, P., additional, Ledesma, C., additional, Yohena, V., additional, Gómez, G., additional, Quintana, R., additional, and Pons-Estel, G., additional

Published
2023
Full Text
View/download PDF

9. AB1298 PATIENTS WITH AXIAL SPONDYLOARTHRITIS HAVE BETTER SARS-CoV-2 OUTCOMES COMPARED WITH PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL SAR-COVID REGISTRY

Author

Bravo, A., primary, Barbich, T., additional, Isnardi, C., additional, Citera, G., additional, Schneeberger, E. E., additional, Quintana, R., additional, Pisoni, C., additional, Pera, M., additional, Velozo, E., additional, Pereira, D. A., additional, Alba, P., additional, Albiero, J. A., additional, Villafañe, J., additional, Maldonado Ficco, H., additional, Savio, V., additional, Aguero, S. E., additional, Rojas Tessel, R., additional, Quaglia, M. I., additional, Gálvez Elkin, M. S., additional, Pendon, G. P., additional, Aeschlimann, C., additional, Rodriguez Gil, G. F., additional, Viola, M., additional, Romeo, C., additional, Maldini, C., additional, Conti, S. M., additional, Gallo, R., additional, Ibañez Zurlo, L., additional, Tamborenea, M. N., additional, Pineda Vidal, S. I., additional, Guaglianone, D., additional, Mareco, J. M., additional, Goizueta, C., additional, Novatti, E., additional, Guzzanti, F., additional, Gómez, G., additional, Roberts, K., additional, and Pons-Estel, G., additional

Published
2023
Full Text
View/download PDF

10. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Author

Sparks, J, Wallace, Z, Seet, A, Gianfrancesco, M, Izadi, Z, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Lawson-Tovey, S, Trupin, L, Rush, S, Katz, P, Schmajuk, G, Jacobsohn, L, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Pons-Estel, G, Isnardi, C, Berbotto, G, Hsu, T, D'Silva, K, Patel, N, Kearsley-Fleet, L, Schafer, M, Ribeiro, S, Al Emadi, S, Tidblad, L, Scire, C, Raffeiner, B, Thomas, T, Flipo, R, Avouac, J, Seror, R, Bernardes, M, Cunha, M, Hasseli, R, Schulze-Koops, H, Muller-Ladner, U, Specker, C, De Souza, V, Da Mota, L, Gomides, A, Dieude, P, Nikiphorou, E, Kronzer, V, Singh, N, Ugarte-Gil, M, Wallace, B, Akpabio, A, Thomas, R, Bhana, S, Costello, W, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Robinson, P, Machado, P, Yazdany, J, Sparks J. A., Wallace Z. S., Seet A. M., Gianfrancesco M. A., Izadi Z., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Lawson-Tovey S., Trupin L., Rush S., Katz P., Schmajuk G., Jacobsohn L., Wise L., Gilbert E. L., Duarte-Garcia A., Valenzuela-Almada M. O., Pons-Estel G. J., Isnardi C. A., Berbotto G. A., Hsu T. Y. -T., D'Silva K. M., Patel N. J., Kearsley-Fleet L., Schafer M., Ribeiro S. L. E., Al Emadi S., Tidblad L., Scire C. A., Raffeiner B., Thomas T., Flipo R. -M., Avouac J., Seror R., Bernardes M., Cunha M. M., Hasseli R., Schulze-Koops H., Muller-Ladner U., Specker C., De Souza V. A., Da Mota L. M. H., Gomides A. P. M., Dieude P., Nikiphorou E., Kronzer V. L., Singh N., Ugarte-Gil M. F., Wallace B., Akpabio A., Thomas R., Bhana S., Costello W., Grainger R., Hausmann J. S., Liew J. W., Sirotich E., Sufka P., Robinson P. C., MacHado P. M., Yazdany J., Sparks, J, Wallace, Z, Seet, A, Gianfrancesco, M, Izadi, Z, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Lawson-Tovey, S, Trupin, L, Rush, S, Katz, P, Schmajuk, G, Jacobsohn, L, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Pons-Estel, G, Isnardi, C, Berbotto, G, Hsu, T, D'Silva, K, Patel, N, Kearsley-Fleet, L, Schafer, M, Ribeiro, S, Al Emadi, S, Tidblad, L, Scire, C, Raffeiner, B, Thomas, T, Flipo, R, Avouac, J, Seror, R, Bernardes, M, Cunha, M, Hasseli, R, Schulze-Koops, H, Muller-Ladner, U, Specker, C, De Souza, V, Da Mota, L, Gomides, A, Dieude, P, Nikiphorou, E, Kronzer, V, Singh, N, Ugarte-Gil, M, Wallace, B, Akpabio, A, Thomas, R, Bhana, S, Costello, W, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Robinson, P, Machado, P, Yazdany, J, Sparks J. A., Wallace Z. S., Seet A. M., Gianfrancesco M. A., Izadi Z., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Lawson-Tovey S., Trupin L., Rush S., Katz P., Schmajuk G., Jacobsohn L., Wise L., Gilbert E. L., Duarte-Garcia A., Valenzuela-Almada M. O., Pons-Estel G. J., Isnardi C. A., Berbotto G. A., Hsu T. Y. -T., D'Silva K. M., Patel N. J., Kearsley-Fleet L., Schafer M., Ribeiro S. L. E., Al Emadi S., Tidblad L., Scire C. A., Raffeiner B., Thomas T., Flipo R. -M., Avouac J., Seror R., Bernardes M., Cunha M. M., Hasseli R., Schulze-Koops H., Muller-Ladner U., Specker C., De Souza V. A., Da Mota L. M. H., Gomides A. P. M., Dieude P., Nikiphorou E., Kronzer V. L., Singh N., Ugarte-Gil M. F., Wallace B., Akpabio A., Thomas R., Bhana S., Costello W., Grainger R., Hausmann J. S., Liew J. W., Sirotich E., Sufka P., Robinson P. C., MacHado P. M., and Yazdany J.

Abstract

Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA). Methods We analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders. Results Of 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity. Conclusions People with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.

Published
2021

11. Risk of severe COVID-19 associated with immune-modifying drugs: Data from PsoProtect and Global Rheumatology Alliance registries.

Author

Mahil, S, Schaefer, M, Dand, N, Yiu, Z, Hyrich, K, Strangfeld, A, Yates, M, Carmona, L, Gossec, L, Mateus, E, Lawson-Tovey, S, Wiek, D, Jacobsohn, L, Isnardi, C, Quintana, R, Soriano, E, Wallace, Z, Bhana, S, Gore-Massey, M, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Mason, K, Tsakok, T, Meynell, F, Coker, B, Vincent, A, Urmston, D, Mcateer, H, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Di Meglio, P, Contreras, C, Choon, S, Capon, F, Torres, T, Naldi, L, Weinman, J, Brown, M, Galloway, J, Norton, S, Lambert, J, Spuls, P, Van Huizen, A, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Langan, S, Sufka, P, Robinson, P, Yazdany, J, Griffiths, C, Barker, J, Machado, P, Smith, C, Mahil SK, Schaefer M, Dand N, Yiu ZZN, Hyrich KL, Strangfeld A, Yates M, Carmona L, Gossec L, Mateus EF, Lawson-Tovey S, Wiek D, Jacobsohn L, Isnardi CA, Quintana R, Soriano ER, Wallace ZS, Bhana S, Gore-Massey M, Grainger R, Hausmann JS, Liew JW, Sirotich E, Mason KJ, Tsakok T, Meynell F, Coker B, Vincent A, Urmston D, McAteer H, Vesty A, Kelly J, Lancelot C, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Di Meglio P, Contreras CR, Choon SE, Capon F, Torres T, Naldi L, Weinman J, Brown MA, Galloway JB, Norton S, Lambert J, Spuls P, Van Huizen AM, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Langan SM, Sufka P, Robinson PC, Yazdany J, Griffiths CEM, Barker JN, Machado PM, Smith CH., Mahil, S, Schaefer, M, Dand, N, Yiu, Z, Hyrich, K, Strangfeld, A, Yates, M, Carmona, L, Gossec, L, Mateus, E, Lawson-Tovey, S, Wiek, D, Jacobsohn, L, Isnardi, C, Quintana, R, Soriano, E, Wallace, Z, Bhana, S, Gore-Massey, M, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Mason, K, Tsakok, T, Meynell, F, Coker, B, Vincent, A, Urmston, D, Mcateer, H, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Di Meglio, P, Contreras, C, Choon, S, Capon, F, Torres, T, Naldi, L, Weinman, J, Brown, M, Galloway, J, Norton, S, Lambert, J, Spuls, P, Van Huizen, A, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Langan, S, Sufka, P, Robinson, P, Yazdany, J, Griffiths, C, Barker, J, Machado, P, Smith, C, Mahil SK, Schaefer M, Dand N, Yiu ZZN, Hyrich KL, Strangfeld A, Yates M, Carmona L, Gossec L, Mateus EF, Lawson-Tovey S, Wiek D, Jacobsohn L, Isnardi CA, Quintana R, Soriano ER, Wallace ZS, Bhana S, Gore-Massey M, Grainger R, Hausmann JS, Liew JW, Sirotich E, Mason KJ, Tsakok T, Meynell F, Coker B, Vincent A, Urmston D, McAteer H, Vesty A, Kelly J, Lancelot C, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Di Meglio P, Contreras CR, Choon SE, Capon F, Torres T, Naldi L, Weinman J, Brown MA, Galloway JB, Norton S, Lambert J, Spuls P, Van Huizen AM, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Langan SM, Sufka P, Robinson PC, Yazdany J, Griffiths CEM, Barker JN, Machado PM, and Smith CH.

Published
2022

12. POS0660 SURVIVAL AND SAFETY OF BIOLOGICAL AND TARGETED SYNTHETIC THERAPIES. 10 YEARS OF REAL-LIFE DATA. BIOABASAR 3.0 REGISTRY

Author

Brigante, A., primary, Isnardi, C. A., additional, Quintana, R., additional, Gómez, G., additional, Roberts, K., additional, Haye, M., additional, Costi, A. C., additional, Perez, N., additional, Astesana, P., additional, Smichowski, A. M., additional, Sorrentino, L., additional, Alcivar Navarrete, J., additional, Raggio, J. C., additional, Viola, M., additional, Saurit, V., additional, Petkovic, I. E., additional, Kirmayr, K. I., additional, Catay, E., additional, D’Angelo, M. E., additional, Pons-Estel, B., additional, Paira, S., additional, Bovea Castelblanco, G., additional, De La Sota, M. E., additional, Larroude, M. S., additional, Pereira, D. A., additional, Granel, A. B., additional, Callahuara, N., additional, Medina, G., additional, Pisoni, C., additional, Alvarez, A., additional, Fernandez, L., additional, Sacnun, M., additional, Soares de Souza, S., additional, Velozo, E., additional, Aste, N., additional, Kerzberg, E., additional, Gallardo, M. D. L. Á., additional, Savio, V., additional, Gamba, J., additional, Citera, G., additional, Soriano, E., additional, Casado, G., additional, Graf, C., additional, Pons-Estel, G., additional, and Delavega, M., additional

Published
2022
Full Text
View/download PDF

13. OP0249 CHARACTERISTICS ASSOCIATED WITH POOR COVID-19 OUTCOMES IN PEOPLE WITH PSORIASIS AND SPONDYLOARTHRITIS: DATA FROM THE COVID-19 PsoProtect AND GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRIES

Author

Machado, P. M., primary, Schaefer, M., additional, Mahil, S., additional, Dand, N., additional, Gianfrancesco, M., additional, Lawson-Tovey, S., additional, Yiu, Z., additional, Yates, M., additional, Hyrich, K., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Wiek, D., additional, Bhana, S., additional, Gore-Massy, M., additional, Grainger, R., additional, Hausmann, J., additional, Sufka, P., additional, Sirotich, E., additional, Wallace, Z., additional, Olofsson, T., additional, Lomater, C., additional, Romeo, N., additional, Wendling, D., additional, Pham, T., additional, Miceli Richard, C., additional, Fautrel, B., additional, Silva, L., additional, Santos, H., additional, Martins, F. R., additional, Hasseli, R., additional, Pfeil, A., additional, Regierer, A., additional, Isnardi, C., additional, Soriano, E., additional, Quintana, R., additional, Omura, F., additional, Machado Ribeiro, F., additional, Pinheiro, M., additional, Bautista-Molano, W., additional, Alpizar-Rodriguez, D., additional, Saad, C., additional, Dubreuil, M., additional, Haroon, N., additional, Gensler, L. S., additional, Dau, J., additional, Jacobsohn, L., additional, Liew, J., additional, Strangfeld, A., additional, Barker, J., additional, Griffiths, C. E. M., additional, Robinson, P., additional, Yazdany, J., additional, and Smith, C., additional

Published
2022
Full Text
View/download PDF

14. POS0655 SURVIVAL AND SAFETY OF BIOLOGICAL AND TARGETED SYNTHETIC THERAPIES AS REGARDS TO AGE GROUPS. BIOBADASAR 3.0 REGISTRY.

Author

Brigante, A., primary, Isnardi, C. A., additional, Gómez, G., additional, Quintana, R., additional, Haye, M., additional, Roberts, K., additional, García, M., additional, Gomez, G., additional, Gobbi, C., additional, Casado, G., additional, Rebak, J., additional, Dapeña, J. M., additional, Berbotto, G., additional, Viola, M., additional, Saurit, V., additional, Petkovic, I. E., additional, Bertoli, A., additional, Giorgis, P., additional, Diaz, M. P., additional, Catay, E., additional, Exeni, I. E., additional, Pons-Estel, B., additional, Paira, S., additional, Bovea Castelblanco, G., additional, De La Sota, M. E., additional, Larroude, M. S., additional, Pereira, D. A., additional, Granel, A. B., additional, Medina, G., additional, Pisoni, C., additional, Alvarez, A., additional, Aguero, S. E., additional, Fernandez, L., additional, Sacnun, M., additional, Soares de Souza, S., additional, Velozo, E., additional, Aste, N., additional, Castro, C., additional, Lazaro, A., additional, Kerzberg, E., additional, Gallardo, M. D. L. Á., additional, Savio, V., additional, Gamba, J., additional, Secco, A., additional, Citera, G., additional, Soriano, E., additional, Graf, C., additional, Pons-Estel, G., additional, and Delavega, M., additional

Published
2022
Full Text
View/download PDF

15. POS1199 IS PSORIATIC ARTHRITIS A RISK FACTOR FOR SEVERE COVID -19 INFECTION? DATA FROM THE ARGENTINIAN REGISTRY SAR-COVID

Author

Savio, V., primary, Maldini, C., additional, Alba, P., additional, Saurit, V., additional, Berbotto, G., additional, Pisoni, C., additional, Tissera, Y., additional, Nieto, R., additional, Maldonado, F., additional, Ornella, S., additional, Gobbi, C., additional, Baños, A. R., additional, Vivero, F., additional, Exeni, I. E., additional, Cusa, A., additional, Bellomio, V. I., additional, Perez Alamino, R., additional, Gomez, G., additional, Zelaya, D., additional, Risueño, F., additional, Quaglia, M. I., additional, Correa, M. D. L. A., additional, Rojas Tessel, R., additional, Delavega, M., additional, Lazaro, M. A., additional, Mercé, A. L., additional, Finucci, P., additional, Matellan, C. E., additional, Romeo, C., additional, Martire, V., additional, Moyano, S., additional, Martin, M. L., additional, Picco, E., additional, Goizueta, C., additional, Tralice, E. R., additional, Tamborenea, M. N., additional, Subils, G. C., additional, Gallo, R., additional, Pineda Vidal, S. I., additional, Velasco Zamora, J. L., additional, Lloves Schenone, N., additional, Cosentino, V., additional, Rodriguez, F., additional, Diaz, M. P., additional, Viola, M., additional, Mamani Ortega, M. L., additional, Buschiazzo, E., additional, Gómez, G., additional, Roberts, K., additional, Quintana, R., additional, Isnardi, C. A., additional, and Pons-Estel, G., additional

Published
2022
Full Text
View/download PDF

16. AB1101 PREVALENCE OF LONG COVID IN RHEUMATIC DISEASE PATIENTS: ANALYSIS OF SAR COVID REGISTRY

Author

Gonzalez Gomez, C. A., primary, Cosatti, M., additional, Castro Coello, V. V., additional, Haye, M., additional, Tissera, Y., additional, Reyes, A. A., additional, Albiero, J. A., additional, Ornella, S., additional, Alba, P., additional, Gobbi, C., additional, Gamba, M. J., additional, Exeni, I. E., additional, Cusa, A., additional, Gallino Yanzi, J., additional, Bellomio, V. I., additional, Gomez, G., additional, Zelaya, D., additional, Takashima, L., additional, Carlevaris, L., additional, Correa, M. D. L. A., additional, Rojas Tessel, R., additional, García, M., additional, German, N., additional, Mercé, A. L., additional, Bertoli, A., additional, Aguero, S. E., additional, Calvo, M. E., additional, Martire, V., additional, Mauri, M., additional, Martin, M. L., additional, Picco, E., additional, Castrillon Bustamante, D., additional, Ibañez Zurlo, L., additional, Tamborenea, M. N., additional, Subils, G. C., additional, Vasquez, D. L., additional, Soares de Souza, S., additional, Herscovich, N., additional, Raiti, L., additional, Cosentino, V., additional, Rodriguez, F., additional, Ledesma, C., additional, Diaz, M. P., additional, Mamani Ortega, M. L., additional, Castaño, M. S., additional, Gómez, G., additional, Roberts, K., additional, Quintana, R., additional, Isnardi, C. A., additional, Pons-Estel, G., additional, and Pisoni, C., additional

Published
2022
Full Text
View/download PDF

17. POS1200 DIFFERENCES BETWEEN THE FIRST AND THE SECOND WAVE OF SARS-COV-2 INFECTION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES IN ARGENTINA: DATA FROM THE SAR-COVID REGISTRY

Author

Bertoli, A., primary, Muñoz, L., additional, López Pérez, M. J., additional, Sanchez Freytes, L., additional, Castaño, M. S., additional, Saurit, V., additional, Berbotto, G., additional, Alle, G., additional, Severina, M., additional, Nieto, R., additional, Maldonado, F., additional, Pera, M., additional, Cogo, A. K., additional, Baños, A. R., additional, Vivero, F., additional, Pereira, D. A., additional, Cosatti, M., additional, Savio, V., additional, Perez Alamino, R., additional, Medina, M. A., additional, Schmid, M., additional, Risueño, F., additional, Quaglia, M. I., additional, Pendon, G. P., additional, Casalla, L., additional, Delavega, M., additional, Lazaro, M. A., additional, Finucci, P., additional, Morbiducci, J., additional, Romeo, C., additional, Cucchiaro, N., additional, Moyano, S., additional, Barbich, T., additional, Conti, S. M., additional, Goizueta, C., additional, Tralice, E. R., additional, Maldini, C., additional, Rebak, J., additional, Gallo, R., additional, Maid, P., additional, Velasco Zamora, J. L., additional, Lloves Schenone, N., additional, Porta, S., additional, Morales, N. S., additional, Diaz, M. P., additional, Viola, M., additional, Buschiazzo, E., additional, Gómez, G., additional, Roberts, K., additional, Quintana, R., additional, Isnardi, C. A., additional, Pons-Estel, G., additional, and Matellan, C. E., additional

Published
2022
Full Text
View/download PDF

18. AB1094 SAFETY AND EFFICACY OF VACCINES FOR SARS-CoV-2 IN PATIENTS WITH RHEUMATIC AND IMMUNE-MEDIATED INFLAMMATORY DISEASES: DATA FROM THE ARGENTINEAN REGISTRY SAR-CoVAC

Author

Isnardi, C. A., primary, Roberts, K., additional, Quintana, R., additional, Kreimer, J., additional, Echeverria, C., additional, Luna, P. C., additional, Virasoro, B. M., additional, Exeni, I. E., additional, Kogan, N., additional, Correa, M. D. L. A., additional, Pereira, D. A., additional, Zelaya, D., additional, Tissera, Y., additional, Pisoni, C., additional, Gálvez Elkin, M. S., additional, Alonso, C. G., additional, Cogo, A. K., additional, Cosatti, M., additional, Garcia, L., additional, Retamozo, C., additional, Severina, M., additional, Nieto, R., additional, Rosemffet, M., additional, Mussano, E. D., additional, Bertoli, A., additional, Delavega, M., additional, Savio, V., additional, Cosentino, V., additional, Roldan, B., additional, Maldonado Ficco, H., additional, Maid, P., additional, Calle Montoro, C., additional, Fernandez, L., additional, Leguizamón, M. L., additional, Gómez Vara, A. B., additional, Alfaro, M. A., additional, Landi, M., additional, Herscovich, N., additional, Maldini, C., additional, De la Vega Fernandez, S. S., additional, Velozo, E., additional, Giorgis, P., additional, Sattler, M. E., additional, Reyes Gómez, C., additional, Perrotat, L., additional, Reimundes, C., additional, Ezquer, R. A., additional, Saurit, V., additional, Flores Trejo, J., additional, Cerda, O. L., additional, Crespo Rocha, M. G., additional, Carrizo Abarza, V., additional, Strusberg, I., additional, Rojas Tessel, R., additional, Verna, G., additional, Bande, J. M., additional, Farfan, P., additional, Berbotto, G., additional, Pons-Estel, G., additional, and Schneeberger, E. E., additional

Published
2022
Full Text
View/download PDF

19. POS1204 SARS-CoV-2 INFECTION AFTER VACCINATION IN PATIENTS WITH RHEUMATIC DISEASES FROM ARGENTINA

Author

Cosatti, M., primary, D´ Angelo, M. E., additional, Petkovic, I. E., additional, Correa, M. D. L. A., additional, Zelaya, D., additional, Gálvez Elkin, M. S., additional, Cogo, A. K., additional, Retamozo, C., additional, Nieto, R., additional, Mussano, E. D., additional, Cavillon, E. M., additional, Savio, V., additional, Roldan, B., additional, Maid, P., additional, Fernandez, L., additional, Muñoz, L., additional, Leguizamón, M. L., additional, Herscovich, N., additional, Alfaro, M. A., additional, Maldini, C., additional, Giorgis, P., additional, Reyes Gómez, C., additional, Reimundes, C., additional, Saurit, V., additional, Cerda, O. L., additional, Crespo Rocha, M. G., additional, Strusberg, I., additional, Verna, G., additional, Quaglia, M. I., additional, Picco, E., additional, Catalan Pellet, S., additional, Galan, M., additional, Troyano, Z., additional, Perandones, M., additional, Kreimer, J., additional, Luna, P. C., additional, Echeverria, C., additional, Virasoro, B. M., additional, Roberts, K., additional, Isnardi, C. A., additional, Schneeberger, E. E., additional, Pons-Estel, G., additional, and Pisoni, C., additional

Published
2022
Full Text
View/download PDF

20. AB1123 EFFICACY AND SAFETY OF SARS-CoV-2 THIRD VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO DID NOT RESPOND AFTER PRIMARY TWO-DOSE REGIMEN

Author

Isnardi, C. A., primary, Cerda, O. L., additional, Schneeberger, E. E., additional, Landi, M., additional, Calle Montoro, C., additional, Alfaro, M. A., additional, Roldan, B., additional, Gómez Vara, A. B., additional, Giorgis, P., additional, Ezquer, R. A., additional, Crespo Rocha, M. G., additional, Reyes Gómez, C., additional, Correa, M. D. L. A., additional, Rosemffet, M., additional, Carrizo Abarza, V., additional, Catalan Pellet, S., additional, Perandones, M., additional, Reimundes, C., additional, Cruces, L., additional, Yesica, L., additional, Turk, G., additional, Quiroga, F., additional, Laufer, N., additional, Quintana, R., additional, Delavega, M., additional, Maid, P., additional, Pons-Estel, G., additional, and Citera, G., additional

Published
2022
Full Text
View/download PDF

21. POS1201 SAFETY OF SARS-COV-2 VACCINES IN PATIENTS WITH RHEUMATIC DISEASES: DATA FROM THE NATIONAL REGISTRY SAR-CoVAC FROM ARGENTINA

Author

Cosatti, M., primary, D´ Angelo, M. E., additional, Petkovic, I. E., additional, Kogan, N., additional, Pereira, D. A., additional, Tissera, Y., additional, Toledo, M. V., additional, Alonso, C. G., additional, Garcia, L., additional, Severina, M., additional, Rosemffet, M., additional, Bertoli, A., additional, Delavega, M., additional, Cosentino, V., additional, Maldonado Ficco, H., additional, Calle Montoro, C., additional, De la Vega Fernandez, S. S., additional, Berbotto, G., additional, Rollano Perasso, A., additional, Gómez Vara, A. B., additional, Landi, M., additional, Velozo, E., additional, Sattler, M. E., additional, Perrotat, L., additional, Ezquer, R. A., additional, Flores Trejo, J., additional, Farfan, P., additional, Rojas Tessel, R., additional, Carrizo Abarza, V., additional, Bande, J. M., additional, Hernandez, B., additional, Papagno, M. J., additional, Rodriguez, L. A., additional, Martin Koller, V., additional, Montoya, F., additional, Kreimer, J., additional, Luna, P. C., additional, Echeverria, C., additional, Virasoro, B. M., additional, Roberts, K., additional, Isnardi, C. A., additional, Schneeberger, E. E., additional, Pons-Estel, G., additional, and Pisoni, C., additional

Published
2022
Full Text
View/download PDF

22. POS1238 GLUCOCORTICOIDS, RITUXIMAB AND THE PRESENCE OF INTERSTITIAL LUNG DISEASE ARE ASSOCIATED WITH POOR OUTCOMES OF THE SARS-COV-2 INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL REGISTRY SAR-COVID.

Author

Gómez Vara, A. B., primary, Barbich, T., additional, Isnardi, C. A., additional, Schneeberger, E. E., additional, Citera, G., additional, Castro Coello, V. V., additional, Baez, R., additional, Haye, M., additional, Reyes, A. A., additional, Albiero, J. A., additional, Tanten, R., additional, Velozo, E., additional, Alba, P., additional, Gamba, M. J., additional, Alonso, C. G., additional, Maldonado Ficco, H., additional, Gallino Yanzi, J., additional, Savio, V., additional, Asnal, C., additional, Matellan, C., additional, Takashima, L., additional, Carlevaris, L., additional, Gálvez Elkin, M. S., additional, Scafati, J., additional, García, M., additional, German, N., additional, Werner, M. L., additional, Aeschlimann, C., additional, Aguero, S. E., additional, Calvo, M. E., additional, Gonzalez Lucero, L., additional, Rodriguez Gil, G. F., additional, Mauri, M., additional, Petruzzelli, S., additional, Castrillon Bustamante, D., additional, Ibañez Zurlo, L., additional, Alonso, D., additional, Tomas, J. L., additional, Vasquez, D. L., additional, Soares de Souza, S., additional, Herscovich, N., additional, Raiti, L., additional, Mareco, J. M., additional, Guaglianone, D., additional, Ledesma, C., additional, Diaz, M. P., additional, Bedoya, M. E., additional, Kisluk, B., additional, Gómez, G., additional, Roberts, K., additional, Quintana, R., additional, and Pons-Estel, G., additional

Published
2022
Full Text
View/download PDF

24. PATIENTS WITH AXIAL SPONDYLOARTHRITIS HAVE BETTER SARS-COV-2 OUTCOMES COMPARED WITH PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL SAR-COVID REGISTRY.

Author

Bravo, A., Barbich, T., Isnardi, C., Citera, G., Schneeberger, E. E., Quintana, R., Pisoni, C., Pera, M., Velozo, E., Pereira, D. A., Alba, P., Albiero, J. A., Villafañe, J., Ficco, H. Maldonado, Savio, V., Aguero, S. E., Tessel, R. Rojas, Quaglia, M. I., Elkin, M. S. Gálvez, and Pendon, G. P.

Published
2023
Full Text
View/download PDF

25. EFFECT OF ABO AND RH BLOOD TYPE ON SARSCOV-2 INFECTION SEVERITY IN PATIENTS WITH RHEUMATIC DISEASES: DATA FROM THE NATIONAL SAR-COVID REGISTRY.

Author

Valdez Donelli, F., Carrizo Abarza, V., Isnardi, C. A., Schneeberger, E. E., Citera, G., D'Angelo, M. E., Ornella, S., Haye, M., Alonso, C. G., Severina, M., Alle, G., Cosatti, M., Yanzi, J. Gallino, Medina, M. A., Perez Alamino, R., Lloves Schenone, N., Correa, M. D. L. A., De la Vega, M., Carlevaris, L., and Cucchiaro, N.

Published
2023
Full Text
View/download PDF

27. AB0214 SURVIVAL, EFFICACY AND SAFETY OF GOLIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS: DATA FROM AN ARGENTINEAN COHORT

Author

Isnardi, C. A., primary, Civit De Garignani, E. E., additional, García Ciccarelli, A., additional, Sanchez Alcover, J., additional, Garcia Salinas, R., additional, Magri, S., additional, Albiero, E., additional, Gobbi, C., additional, Velozo, E., additional, Soriano, E., additional, Brom, M., additional, Zacariaz, J., additional, Strusberg, I., additional, Baravalle, M., additional, Castaños, S., additional, Morales, L., additional, Paira, S., additional, Calvo, R., additional, Ortiz, A., additional, Perez Alamino, R., additional, Maldonado Ficco, H., additional, and Citera, G., additional

Published
2021
Full Text
View/download PDF

28. POS0312 HOW DOES THE PRESENCE OF DEPRESSION IMPACT ON DISEASE ACTIVITY SCORES IN PATIENTS WITH RHEUMATOID ARTHRITIS?

Author

Isnardi, C. A., primary, Schneeberger, E. E., additional, Capelusnik, D., additional, Bazzarelli, M., additional, Barloco, L., additional, Blanco, E. S., additional, Benitez, A., additional, Benavidez, F., additional, Scarafia, S., additional, Lazaro, M. A., additional, Perez Alamino, R., additional, Colombres, F., additional, Kohan, M. P., additional, Sosa, J., additional, Gonzalez Lucero, L., additional, Barbaglia, A. L., additional, Maldonado Ficco, H., additional, and Citera, G., additional

Published
2021
Full Text
View/download PDF

29. POS1188 COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: COMPARISON OF DATA FROM THE ARGENTINE REGISTRY (SAR-COVID), WITH THE LATIN AMERICAN AND GLOBAL REGISTRY (GLOBAL RHEUMATOLOGY ALLIANCE)

Author

Reyes, A. A., primary, Alle, G., additional, Tanten, R., additional, Scolnik, M., additional, Soriano, E., additional, Berbotto, G., additional, Haye, M., additional, Gamba, M. J., additional, Nieto, R., additional, García, M., additional, Savio, V., additional, Gonzalez Lucero, L., additional, Alba, P., additional, Takashima, L., additional, Risueño, F., additional, Casalla, L., additional, Cucchiaro, N., additional, Bertoli, A., additional, Porta, S., additional, Maldini, C., additional, Gallo, R., additional, Goizueta, C., additional, Picco, E., additional, Quintana, R., additional, Roberts, K., additional, Isnardi, C. A., additional, and Pons-Estel, G., additional

Published
2021
Full Text
View/download PDF

30. POS1208 EPIDEMIOLOGY AND OUTCOMES OF PATIENTS WITH RHEUMATIC DISEASES AND SARS-CoV-2 INFECTION: DATA FROM THE ARGENTINEAN SAR-COVID REGISTRY

Author

Isnardi, C. A., primary, Quintana, R., additional, Roberts, K., additional, Castro Coello, V. V., additional, Reyes, A. A., additional, Tissera, Y., additional, Cosatti, M., additional, Rojas Tessel, R., additional, Scafati, J., additional, Barbich, T., additional, Gálvez Elkin, M. S., additional, Rodriguez Gil, G. F., additional, Moyano, S., additional, Werner, M. L., additional, Rebak, J., additional, Morbiducci, J., additional, Martire, V., additional, Castaño, M. S., additional, Dieguez, C., additional, Subils, G. C., additional, and Pons-Estel, G., additional

Published
2021
Full Text
View/download PDF

31. POS1186 EFFECT OF SOCIO-ECONOMIC STATUS AND EDUCATIONAL LEVEL ON COVID-19 OUTCOMES IN PATIENTS WITH RHEUMATIC DISEASES FROM ARGENTINA: DATA FROM THE SAR-COVID REGISTRY

Author

Sorrentino, L., primary, Rebak, J., additional, Maldonado, F., additional, Castro Coello, V. V., additional, Brigante, A., additional, Hamaui, A., additional, Dubinsky, D., additional, Baez, R., additional, Pisoni, C., additional, Gobbi, C., additional, Carlevaris, L., additional, Tanten, R., additional, Cogo, A. K., additional, Delavega, M., additional, Perez Alamino, R., additional, Lazaro, M. A., additional, Pera, M., additional, Pineda Vidal, S. I., additional, Calvo, M. E., additional, Guaglianone, D., additional, Alonso, C. G., additional, Guinsburg, M., additional, Retamozo, C., additional, Aeschlimann, C., additional, Quintana, R., additional, Roberts, K., additional, Isnardi, C. A., additional, and Pons Estel, G., additional

Published
2021
Full Text
View/download PDF

32. COVID-19 IN PATIENTS WITH RHEUMATIC IMMUNEMEDIATED INFLAMMATORY DISEASES IN AMERICA: DIFFERENCES AND SIMILARITIES BETWEEN MEXICO AND ARGENTINA.

Author

Isnardi, C. A., Alpizar-Rodriguez, D., Martínez-Martínez, M. U., Quintana, R., Petkovic, I. E., Ornella, S., Castro Coello, V. V., Velozo, E., Zelaya, D., Severina, M., Cogo, A. K., Nieto, R., Pereira, D. A., Colunga-Pedraza, I. J., Irazoque-Palazuelos, F., Reyes Cordero, G. C., Rodriguez-Reyne, T. S., Veloz Aranda, J. A., Skinner Taylor, C. M., and Juarez Mora, I. M.

Published
2023
Full Text
View/download PDF

33. CLINICAL CHARACTERISTICS OF SARS-COV-2 INFECTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN ARGENTINA: DATA FROM THE SAR-COVID NATIONAL REGISTRY.

Author

Isnardi, C. A., Roberts, K., Tissera, Y., Petkovic, I., Berbotto, G., Gobbi, C., Tanten, R., Cogo, A. K., Asnal, C., Baños, A. R., Vivero, F., Schmid, M., Lazaro, M. A., German, N., Takashima, L., Scafati, J., Werner, M. L., Casalla, L., De la Vega Fernandez, S. S., and Bustamante, D. Castrillon

Published
2023
Full Text
View/download PDF

34. CARDIOVASCULAR OUTCOMES OF ANTI-TNF ALFA AND JAK INHIBITORS IN PATIENTS WITH RHEUMATOID AND PSORIATIC ARTHRITIS. REAL WORLD EVIDENCE AND INSIGHTS OF BIOBADASAR 3.0 REGISTRY.

Author

Brigante, J. A., Roberts, K., Isnardi, C. A., Gómez, G., Holguín Arias, L. L., Pons-Estel, B., Gamba, J., Haye, M., Dapeña, J. M., Secco, A., Savio, V., Soliz Cordero, C., Gobbi, C., Velozo, E., Catay, E., Aste, N., Medina, G., Exeni, I. E., Gomez, G., and Pereira, D. A.

Published
2023
Full Text
View/download PDF

38. IFMIF-EVEDA RF power system

Author

David Regidor, Arriaga, A., Calvo, J., Ibarra, A., Kirpitchev, I., Méndez, P., Molla, J., Salom, A., Weber, M., Beauvais, P. Y., Desmons, M., Mosnier, A., Vandeplassche, D., Cara, P., Forteza, J. M., González, J. M., Isnardi, C. R., Cvetkovic, Z., Golubicic, Z., Méndez, C., La Cruz, J., Ceballos, S. J., Abs, M., and Nactergal, B.

39. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Author

Maria Margarida Cunha, Gabriela Schmajuk, Rebecca Hasseli, Namrata Singh, Tiffany Y.T. Hsu, Milena A. Gianfrancesco, Anja Strangfeld, Ranjeny Thomas, Naomi J Patel, Thierry Thomas, Philippe Dieudé, Kimme L. Hyrich, Emily Sirotich, Laura Trupin, Liselotte Tidblad, Jinoos Yazdany, René Marc Flipo, Licia Maria Henrique da Mota, Andrea M Seet, Samar Al Emadi, Carolina A. Isnardi, Saskia Lawson-Tovey, Alí Duarte-García, Hendrik Schulze-Koops, Manuel F. Ugarte-Gil, Vanessa L. Kronzer, Philip Robinson, Lindsay Jacobsohn, Elsa F Mateus, Pedro Machado, Ana Paula Monteiro Gomides, Jean W. Liew, Guillermo A. Berbotto, Miguel Bernardes, Patricia P. Katz, Martin Schäfer, Guillermo J. Pons-Estel, Ulf Müller-Ladner, Jeffrey A. Sparks, Elena Nikiphorou, Christof Specker, Paul Sufka, Zara Izadi, Loreto Carmona, Stephanie Rush, Sandra Lúcia Euzébio Ribeiro, Maria O Valenzuela-Almada, Kristin M. D’Silva, Emily L Gilbert, Raphaèle Seror, Laure Gossec, Beth I Wallace, Viviane Angelina de Souza, Akpabio Akpabio, Jérôme Avouac, Leanna Wise, Wendy Costello, Zachary S. Wallace, Suleman Bhana, Jonathan S. Hausmann, Lianne Kearsley-Fleet, Bernd Raffeiner, Carlo Alberto Scirè, Rebecca Grainger, Sparks, J, Wallace, Z, Seet, A, Gianfrancesco, M, Izadi, Z, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Lawson-Tovey, S, Trupin, L, Rush, S, Katz, P, Schmajuk, G, Jacobsohn, L, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Pons-Estel, G, Isnardi, C, Berbotto, G, Hsu, T, D'Silva, K, Patel, N, Kearsley-Fleet, L, Schafer, M, Ribeiro, S, Al Emadi, S, Tidblad, L, Scire, C, Raffeiner, B, Thomas, T, Flipo, R, Avouac, J, Seror, R, Bernardes, M, Cunha, M, Hasseli, R, Schulze-Koops, H, Muller-Ladner, U, Specker, C, De Souza, V, Da Mota, L, Gomides, A, Dieude, P, Nikiphorou, E, Kronzer, V, Singh, N, Ugarte-Gil, M, Wallace, B, Akpabio, A, Thomas, R, Bhana, S, Costello, W, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Robinson, P, Machado, P, and Yazdany, J

Subjects
Male, medicine.medical_specialty, abatacept, Coronavirus disease 2019 (COVID-19), Immunology, tumour necrosis factor inhibitors, tumour necrosis factor inhibitor, Antirheumatic Agents/therapeutic use, Rheumatoid Arthritis, Severity of Illness Index, General Biochemistry, Genetics and Molecular Biology, Arthritis, Rheumatoid, 03 medical and health sciences, 0302 clinical medicine, rituximab, Rheumatology, Arthritis, Rheumatoid/complications, Internal medicine, medicine, Immunology and Allergy, Humans, 030212 general & internal medicine, Registries, Interleukin 6, Aged, 030203 arthritis & rheumatology, biology, business.industry, SARS-CoV-2, Abatacept, Confounding, COVID-19, rheumatoid arthriti, Middle Aged, medicine.disease, Drug class, Rheumatoid arthritis, Antirheumatic Agents, COVID-19/complications, biology.protein, Rituximab, Female, business, medicine.drug
Abstract

ObjectiveTo investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).MethodsWe analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders.ResultsOf 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity.ConclusionsPeople with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.

Published
2021

40. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19

Author

Ryan C. Ungaro, Therapy Psoriasis Patient Registry for Outcomes, Leanna Wise, Hanns-Martin Lorenz, Pascal Claudepierre, Suleman Bhana, Michael D. Kappelman, Anja Strangfeld, Loreto Carmona, Wendy Costello, Eva Klingberg, Elsa F Mateus, Pedro Machado, Rosana Quintana, Jeffrey A. Sparks, Mark Yates, Zara Izadi, Erica J. Brenner, Nick Dand, Jean W. Liew, Bimba F. Hoyer, Gabriela Schmajuk, Alí Duarte-García, Carolina A. Isnardi, Saskia Lawson-Tovey, Kristin M. D’Silva, Patricia P. Katz, Manasi Agrawal, Jinoos Yazdany, Philippe Goupille, Zenas Z N Yiu, Zachary S. Wallace, Enrique R. Soriano, Catherine H. Smith, Ana Rita Cruz-Machado, Emily L Gilbert, Naomi J Patel, Maria O Valenzuela-Almada, Jonathan S. Hausmann, Christopher E.M. Griffiths, Giovanna Cuomo, Emily Sirotich, Stephanie Rush, Laura Trupin, Ana Carolina Mazeda Pereira, Xian Zhang, Kimme L. Hyrich, Jean-Frederic Colombel, René-Marc Flipo, Rebecca Hasseli, Alain Cantagrel, Satveer K. Mahil, Marta Caprioli, Andrea M Seet, Samar Al Emadi, Philip Robinson, Claudia Diniz Lopes Marques, Ricardo Machado Xavier, Rebecca Grainger, Tiffany Y-T Hsu, Lindsay Jacobsohn, Adriana Maria Kakehasi, Paul Sufka, Milena A. Gianfrancesco, Alexander Pfeil, Jonathan Barker, Izadi, Z., Brenner, E. J., Mahil, S. K., Dand, N., Yiu, Z. Z. N., Yates, M., Ungaro, R. C., Zhang, X., Agrawal, M., Colombel, J. -F., Gianfrancesco, M. A., Hyrich, K. L., Strangfeld, A., Carmona, L., Mateus, E. F., Lawson-Tovey, S., Klingberg, E., Cuomo, G., Caprioli, M., Cruz-Machado, A. R., Mazeda Pereira, A. C., Hasseli, R., Pfeil, A., Lorenz, H. -M., Hoyer, B. F., Trupin, L., Rush, S., Katz, P., Schmajuk, G., Jacobsohn, L., Seet, A. M., Al Emadi, S., Wise, L., Gilbert, E. L., Duarte-Garcia, A., Valenzuela-Almada, M. O., Isnardi, C. A., Quintana, R., Soriano, E. R., Hsu, T. Y. -T., D'Silva, K. M., Sparks, J. A., Patel, N. J., Xavier, R. M., Marques, C. D. L., Kakehasi, A. M., Flipo, R. -M., Claudepierre, P., Cantagrel, A., Goupille, P., Wallace, Z. S., Bhana, S., Costello, W., Grainger, R., Hausmann, J. S., Liew, J. W., Sirotich, E., Sufka, P., Robinson, P. C., Machado, P. M., Griffiths, C. E. M., Barker, J. N., Smith, C. H., Yazdany, J., Kappelman, M. D., APH - Methodology, APH - Quality of Care, AII - Inflammatory diseases, and Dermatology

Subjects
Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Azathioprine, Comorbidity, Lower risk, Inflammatory bowel disease, Arthritis, Rheumatoid, Internal medicine, Psoriasis, medicine, Humans, Registries, Pandemics, Retrospective Studies, Original Investigation, SARS-CoV-2, Tumor Necrosis Factor-alpha, business.industry, Research, COVID-19, Retrospective cohort study, General Medicine, Odds ratio, Middle Aged, Inflammatory Bowel Diseases, medicine.disease, TNF inhibitor, Hospitalization, Online Only, Infectious Diseases, Rheumatoid arthritis, Drug Therapy, Combination, Female, Tumor Necrosis Factor Inhibitors, business, medicine.drug
Abstract

Key Points Question Is receipt of tumor necrosis factor (TNF) inhibitor monotherapy at the time of COVID-19 diagnosis associated with adverse COVID-19 outcomes compared with other treatment regimens among patients with immune-mediated inflammatory diseases (IMIDs)? Findings In this cohort study of 6077 patients with IMIDs and COVID-19, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, or Janus kinase inhibitor monotherapy were each associated with significantly higher odds of hospitalization or death compared with TNF inhibitor monotherapy. Meaning This study’s findings support the continued use of TNF inhibitor monotherapy among individuals with IMIDs during the pandemic., Importance Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact of COVID-19 among individuals with IMIDs who are receiving TNF inhibitors remains insufficiently understood. Objective To examine the association between the receipt of TNF inhibitor monotherapy and the risk of COVID-19–associated hospitalization or death compared with other commonly prescribed immunomodulatory treatment regimens among adult patients with IMIDs. Design, Setting, and Participants This cohort study was a pooled analysis of data from 3 international COVID-19 registries comprising individuals with rheumatic diseases, inflammatory bowel disease, and psoriasis from March 12, 2020, to February 1, 2021. Clinicians directly reported COVID-19 outcomes as well as demographic and clinical characteristics of individuals with IMIDs and confirmed or suspected COVID-19 using online data entry portals. Adults (age ≥18 years) with a diagnosis of inflammatory arthritis, inflammatory bowel disease, or psoriasis were included. Exposures Treatment exposure categories included TNF inhibitor monotherapy (reference treatment), TNF inhibitors in combination with methotrexate therapy, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, and Janus kinase (Jak) inhibitor monotherapy. Main Outcomes and Measures The main outcome was COVID-19–associated hospitalization or death. Registry-level analyses and a pooled analysis of data across the 3 registries were conducted using multilevel multivariable logistic regression models, adjusting for demographic and clinical characteristics and accounting for country, calendar month, and registry-level correlations. Results A total of 6077 patients from 74 countries were included in the analyses; of those, 3215 individuals (52.9%) were from Europe, 3563 individuals (58.6%) were female, and the mean (SD) age was 48.8 (16.5) years. The most common IMID diagnoses were rheumatoid arthritis (2146 patients [35.3%]) and Crohn disease (1537 patients [25.3%]). A total of 1297 patients (21.3%) were hospitalized, and 189 patients (3.1%) died. In the pooled analysis, compared with patients who received TNF inhibitor monotherapy, higher odds of hospitalization or death were observed among those who received a TNF inhibitor in combination with azathioprine/6-mercaptopurine therapy (odds ratio [OR], 1.74; 95% CI, 1.17-2.58; P = .006), azathioprine/6-mercaptopurine monotherapy (OR, 1.84; 95% CI, 1.30-2.61; P = .001), methotrexate monotherapy (OR, 2.00; 95% CI, 1.57-2.56; P, This cohort study uses data from 3 international registries to examine the association between the receipt of tumor necrosis factor monotherapy and the risk of COVID-19–associated hospitalization or death among adult patients with immune-mediated inflammatory diseases.

Published
2021

41. Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status.

Author

Maguire S, Al-Emadi S, Alba P, Aguiar MC, Al Lawati T, Alle G, Bermas B, Bhana S, Branimir A, Bulina I, Clowse M, Cogo K, Colunga I, Cook C, Cortez KJ, Dao K, Gianfrancesco M, Gore-Massey M, Gossec L, Grainger R, Hausman J, Hsu TYT, Hyrich K, Isnardi C, Kawano Y, Kilding R, Kusevich DA, Lawson-Tovey S, Liew J, McCarthy E, Montgumery A, Moyano S, Nasir N, Padjen I, Papagoras C, Patel NJ, Pera M, Pisoni C, Pons-Estel G, Quiambao AL, Quintana R, Ruderman E, Sattui S, Savio V, Sciascia S, Sencarova M, Morales RS, Siddique F, Sirotich E, Sparks J, Strangfeld A, Sufka P, Tanner H, Tissera Y, Wallace Z, Werner ML, Wise L, Worthing AB, Zell J, Zepa J, Machado PM, Yazdany J, Robinson P, and Conway R

Subjects
Pregnancy, Infant, Newborn, Female, Humans, COVID-19 Vaccines, COVID-19 Testing, Vaccination, COVID-19 epidemiology, COVID-19 prevention & control, Rheumatic Diseases drug therapy, Premature Birth
Abstract

Objective: To describe obstetric outcomes based on COVID-19 vaccination status, in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy., Methods: Data regarding pregnant women entered into the COVID-19 Global Rheumatology Alliance registry from 24 March 2020-25 February 2022 were analysed. Obstetric outcomes were stratified by number of COVID-19 vaccine doses received prior to COVID-19 infection in pregnancy. Descriptive differences between groups were tested using the chi-squared or Fisher's exact test., Results: There were 73 pregnancies in 73 women with RMD and COVID-19. Overall, 24.7% (18) of pregnancies were ongoing, while of the 55 completed pregnancies, 90.9% (50) of pregnancies resulted in livebirths. At the time of COVID-19 diagnosis, 60.3% (n = 44) of women were unvaccinated, 4.1% (n = 3) had received one vaccine dose while 35.6% (n = 26) had two or more doses. Although 83.6% (n = 61) of women required no treatment for COVID-19, 20.5% (n = 15) required hospital admission. COVID-19 resulted in delivery in 6.8% (n = 3) of unvaccinated women and 3.8% (n = 1) of fully vaccinated women. There was a greater number of preterm births (PTB) in unvaccinated women compared with fully vaccinated 29.5% (n = 13) vs 18.2% (n = 2)., Conclusions: In this descriptive study, unvaccinated pregnant women with RMD and COVID-19 had a greater number of PTB compared with those fully vaccinated against COVID-19. Additionally, the need for COVID-19 pharmacological treatment was uncommon in pregnant women with RMD regardless of vaccination status. These results support active promotion of COVID-19 vaccination in women with RMD who are pregnant or planning a pregnancy., (© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.)

Published
2023
Full Text
View/download PDF

42. Validation of the adjusted global antiphospholipid syndrome score in systemic lupus erythematosus patients in Argentina.

Author

Garcia L, Velloso MS, Martire MV, Savy F, Arizpe F, Garcia N, Testi A, Pena C, Costi AC, Isnardi C, Capelusnik D, Mazza S, Curi YS, Collado V, Rodriguez MF, Scarafia S, Pisoni C, de la Torre M, Seewald A, Riva ME, and Garcia M

Subjects
Adult, Antibodies, Antiphospholipid immunology, Antiphospholipid Syndrome complications, Argentina, Female, Heart Disease Risk Factors, Humans, Lupus Erythematosus, Systemic complications, Male, Pregnancy, Pregnancy Complications diagnosis, Retrospective Studies, Risk Assessment methods, Sensitivity and Specificity, Thrombosis etiology, Antiphospholipid Syndrome diagnosis, Lupus Erythematosus, Systemic diagnosis
Abstract

Introduction: Assessment of risk both for pregnancy morbidity and thrombosis in the presence of anti-phospholipid antibodies (aPL) is still a challenge in Systemic Lupus Erythematosus (SLE) patients. The Global Antiphospholipid Syndrome Score (GAPSS) takes into account the aPL profile (criteria and non-criteria aPL), the conventional cardiovascular risk factors and the autoimmune antibody profile. An adjusted model of the score (aGAPSS) excluding anti-phosphatidylserine/Prothrombin (aPS/PT), suggests that the score is able to stratify patients for their rate of events making it widely applicable in daily clinical practice., Objective: To validate the aGAPSS in a multicentric cohort of SLE patients in Argentina., Patients and Methods: consecutive SLE patients with and with andwithout thrombotic events from seven Rheumatologist centers were included. Traditional cardiovascular risk factors, aPL antibodies and medications received (aspirin, hydroxychloroquine and anticoagulation) were collected. The score aGAPSS was calculated for each patient at the last visit by adding together the points corresponding to the risk factors: 1 for hypertension, 3 for dyslipidemia, 4 for LA and B2GPI (IgM or IgG) antibodies and 5 for aCL (IgM or IgG) antibodies. The discriminative ability of the aGAPSS was calculated by measuring the area under the receiver operating characteristic curve (AUC). Multivariate logistic regression analysis was performed to examine the impact of multiple cardiovascular risk factors and laboratory parameters on the occurrence of thrombosis., Results: Two hundred and ninety-six SLE patients were included. One-hundred and twenty-one patients (40.9%) presented thrombotic and/or pregnancy complications. Median aGAPSS was significantly higher in patients who experienced an event (thrombosis and/or pregnancy morbidity) compared with those without [4 (IQR 1-9) versus 1 (IQR 0-5); p < 0.001]. The best cut off point for the diagnosis of thrombosis and/or pregnancy complications was aGAPSS ≥4. Multivariate logistic regression analysis showed that aCL antibodies [OR 2.1 (95% CI 1.16-3.90); p = 0.015] were an independent risk factors for thrombotic events., Conclusions: This score is a simple tool, easy to apply to SLE patients in daily practice. The use of the aGAPSS could change the non-pharmacologic and pharmacologic treatment in higher risk patients to improve their survival.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results